Loading
Neil Kumar received $15.6M in total compensation as Ph.D. Chief Executive Officer of BridgeBio Pharma, Inc. in FY2024. The largest component was $12.5M in stock awards. Source: SEC DEF 14A.
In fiscal year 2024, Neil Kumar, Ph.D. Chief Executive Officer of BridgeBio Pharma, Inc. (BBIO), received total compensation of $15.6 million.
Neil Kumar's compensation breakdown includes: base salary of $988K, bonus of $1.0 million, stock awards valued at $12.5 million, option awards of $1000K, and other compensation of $14K.
BridgeBio Pharma, Inc.'s top 3 named executive officers received combined total compensation of $27.7 million in fiscal year 2024.
The named executive officers disclosed in BridgeBio Pharma, Inc.'s 2024 proxy statement are:Neil Kumar (Ph.D. Chief Executive Officer) with total compensation of $15.6 million, Thomas Trimarchi (Ph.D.(4) President and Chief Financial Officer) with total compensation of $6.5 million, and Brian Stephenson (Ph.D., CFA Former Chief Financial Officer) with total compensation of $5.7 million.
Source Filing
Executive Record
Neil Kumar
Ph.D. Chief Executive Officer
Reported Pay
$15.6M
Summary compensation table total · FY2024
Findings
Reviewing FY2024 compensation of $15.6M against shareholder return and the latest filing-backed pay disclosures.
Spread between reported pay and stock performance is pending computation.
Evidence is sourced from the latest executive compensation filing and return series for BBIO.
Team view
3 executives
Ph.D. Chief Executive Officer
Total PayFY2024
$15.6M
Ph.D.(4) President and Chief Financial Officer
Total PayFY2024
$6.5M
Ph.D., CFA Former Chief Financial Officer
Total PayFY2024
$5.7M
Ask a question about this filing
01FY2024 total compensation breakdown
$15.6M total compensation
Neil Kumar earned $15.6M in FY2024 — here's how that breaks down.
$12.5M
80% of total
$1.0M
7% of total
$1000.0K
6% of total
$987.5K
6% of total
$14.2K
0% of total
A pay-performance summary will appear here once the verdict loads above.
02Pay changes vs. stock performance
1 year of data
Peer context
Dashed line marks the large-cap median compensation benchmark for companies around $15.0B market cap, based on 312 peers in this size band.
03Recent insider trades by officers and directors
~24 trades
04Showing FY2024 data (latest available)
FY2026 does not include director compensation in our current dataset, so we're showing the latest board table we found.
We're loading the latest director compensation and board makeup.
05Take action on executive compensation
Shareholder activism tools
Start or join campaigns to engage with BBIO's board on executive compensation, governance, and shareholder proposals.
Activism Beta — Sign in to start or join campaigns
06For analysts and deep research
Historical compensation data from latest proxy filing
| Year | Executive | Salary | Bonus & Incentive | Stock Awards | Option Awards | Other Adj. | Total |
|---|---|---|---|---|---|---|---|
| 2024 | Neil Kumar Ph.D. Chief Executive Officer | $0.99M | $1.04M | $12.5M | $1.00M | $0.01M | $15.6M |
Salary = base cash pay. Bonus & Incentive combines annual bonus and non-equity plans. Equity amounts are grant-date fair values. Other Adj. captures pension changes, perquisites, and any reconciliation items so the total matches the reported figure.
Get one email when new executive compensation data is filed and processed.
BridgeBio Pharma, Inc. (BBIO) — Key Facts
Last updated Mar 31, 2026 · DEF 14A filed Apr 30, 2025
| CEO | Neil Kumar, Ph.D. Chief Executive Officer |
|---|---|
| Fiscal year | FY2024 |
| Total compensation | $15.6M |
| Base salary | $988K |
| Stock awards | $12.5M |
| Other compensation | $14K |
| Source | DEF 14A, 2025-04-30 |
Neil Kumar, the Ph.D. Chief Executive Officer of BridgeBio Pharma, Inc., received total compensation of $15.6 million in fiscal year 2024. This includes base salary of $987,539 and stock awards valued at $12.5 million.
Neil Kumar's base salary at BridgeBio Pharma, Inc. is $987,539 per year as of fiscal year 2024. However, total compensation including stock awards, bonuses, and other benefits is $15.6 million.
BridgeBio Pharma, Inc.'s CEO, Neil Kumar, earned $15.6 million in total compensation for fiscal year 2024. The majority of this compensation comes from stock awards ($12.5 million) rather than base salary ($987,539).